[{"orgOrder":0,"company":"H3 Biomedicine Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"H3 Biomedicine Presents Data Update on H3B-6545 at San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"H3 Biomedicine Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"H3 Biomedicine Presents Update on Intratumoral E7766 Clinical Program for Advanced Solid Tumors or Lymphomas at AACR-NCI-EORTC Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by H3 Biomedicine Inc
E7766 is a STING (Stimulator of Interferon Genes) agonist with broad specificity to all major genetic variants of human STING. Preclinical studies suggest that treatment with E7766 by intratumoral administration has anti-tumor activity at both local and systemic levels.
The presentations include interim data from H3’s ongoing Phase 1/2 clinical development program, H3B-6545, a potential first-in-class, orally available Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer.